Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Trelegy

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    - PMLiVE

    AstraZeneca shares late-stage results for Airsupra in mild asthma patients

    More than ten million asthma exacerbations occur in the US every year

    - PMLiVE

    AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

    Up to 262 million people worldwide are affected by the chronic respiratory disease

    - PMLiVE

    Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

    The reference medicine holds approvals for multiple HER2-positive breast cancer indications

    - PMLiVE

    Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

    Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

    EU flag

    Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

    There is currently only one treatment authorised for the ultra-rare genetic blistering disease

    EU flag

    CHMP recommends Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

    Approximately 480,000 cases of the mosquito-borne viral disease were reported globally in 2024

    - PMLiVE

    Chiesi report highlights incorrect inhaler use among UK asthma patients

    The long-term lung condition affects around 7.2 million people in the UK

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use

    Approximately 121,000 people are diagnosed with primary advanced or recurrent endometrial cancer each year in Europe

    - PMLiVE

    MHRA urges companies to prepare for Windsor Framework for medicines

    The new UK-wide arrangements for medicines will come into effect on 1 January 2025

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links